http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 14 May 2026 07:15:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Press+Releases/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696 http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html <p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </em></p> <p align="center"><em>Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval</em></p> <p align="center"><em>Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026</em></p> <p align="center"><em>Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy http://www.streetinsider.com/Globe+Newswire/Cellectar+Biosciences+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26489825.html Thu, 14 May 2026 07:15:00 -0400 A.06822034 A.16381631 A.31066700 A.50200171 A.50202612 CLRB CLRBW CLRBZ O.00478238 O.12717630 O.20026344 O.21558387 O.22422661 O.29766696